Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy.

Immune checkpoint inhibitors (ICIs) are pharmaceutical agents capable of disrupting immune checkpoint signaling, leading to T-cell activation and a robust anti-tumor response [...].